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Abstract
The clavulanic acid derived by fermentation of Streptomyces clavuligerus and possessed 
the capability to inactivate a broad range of β-lactamase enzymes. A complex physico-
chemical process involves the binding of clavulanic acid to β-lactamases in which clavu-
lanic acid itself deplete irreversibly along with β-lactamase enzyme rendering amoxicillin 
spared which otherwise would hydrolyze by an enzyme. It is therefore termed as ‘suicide 
‘inhibitor for β-lactamases. We discussed here pharmacokinetic parameters and identi-
fied factors responsible for the variability of absorption of clavulanic acid. The results 
based on individual plasma concentration-time curve of amoxicillin and clavulanic acid 
in an open, randomized, two-way crossover study involving 10 healthy male subjects 
administered with two amoxiclav formulations.
Keywords: clinical, clavulanic acid, pharmacokinetics, variable absorption, AUC total, 
pharmacokinetics, β-lactamase
1. Introduction
Clavulanic acid derived by fermentation of Streptomyces clavuligerus and possessed the capa-
bility to inactivate a broad range of β-lactamase enzymes. The molecular formula of clavula-
nate potassium is C₈H₈KNO₅ with the molecular weight of 237.25. Chemically it is potassium 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
(Z)-(2R,5R)-3-(2-hydroxyethylidine)-7-oxo-4-1-azabicyclo[3.2.0]-heptane-2-carboxylate, 
represented as in Figure 1. Mainly it combines with amoxicillin to broaden its antibacte-
rial spectrum [1]. A complex physicochemical process involve in binding of clavulanic acid 
to β-lactamases in which clavulanic acid itself deplete irreversibly along with β-lactamase 
enzyme rendering amoxicillin spared which otherwise would hydrolyzed by enzyme. It is 
therefore termed as ‘suicide ‘inhibitor for β-lactamases. A very low plasma concentration of 
clavulanic acid is required for this target action. After oral administration the pharmacoki-
netic parameters of both components i.e. amoxicillin and clavulanic acid were similar and 
they did not affect pharmacokinetic parameters of each other [2–6]. This could be one of 
reason for their antimicrobial combination. In combination clavulanic acid and amoxicillin 
used in different composition i.e. 250/125, 500/125 and 850/125 respectively. In this amount 
of amoxicillin varies but that of clavulanic acid remain constant i.e. 125 mg. It would suggest 
that there is no significant amount required for clavulanic acid to inhibit β lactamase enzymes 
[3]. We discussed here pharmacokinetic parameters and identified factors responsible for 
variability of absorption of clavulanic acid and compared it with previous reported data. The 
results based on individual plasma concentration-time curve of amoxicillin and clavulanic 
acid in an open, randomized, two-way crossover study involving 12 healthy male subjects 
administered with two amoxiclav formulations.
2. Parameter which is associated to show variability of absorption
Mainly C
t
 (concentration at time t) is responsible for clinical effects of any drug. When C
t
 is 
higher the AUC (Area under Curve) and C
p
 (plasma concentration) will also show higher 
values. Thus they all are co-related to show any clinical effect but question arises that which 
pharmacokinetic parameter or any other factor is most likely to show variability in absorp-
tion of any drug which would ultimately affect its clinical effect. Clavulanic acid along with 
amoxicillin is well absorbed from stomach after oral administration without having any 
impact of fasting and fed state on the pharmacokinetics of amoxicillin. While relative bioavail-
ability of clavulanic acid becomes reduced when administered after 30 and 150 min of high 
fat breakfast. The logic behind reduced bioavailability of clavulanic acid after ingestion with 
the meal was due to prolong residence time of clavulanic acid in GI due to intragastric tablet 
deposition in the proximal stomach. The half-life of clavulanic acid is 1.0 h and 25–40% of it is 
excreted unchanged in urine following first 6 h of administration. Clavulanic acid is difficult 
to extract out from plasma as it has been bound approximately 25% to human serum and 
therefore required double extraction procedure to observe by liquid chromatography. After 
absorption clavulanic acid is well distributed in body tissues [7].
Figure 1. Structure of clavulanate potassium.
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2.1. Content assay for co-amoxiclav tablets by HPLC
The content assay for co-amoxiclav tablets was carried out by validated HPLC method. 
The method validation was carried out according to USP guidelines. For good and accurate 
resolution and reproducibility of the presented method various suitability considerations 
including tailing factor, retention time, resolution, RSD% of retention time and peak areas 
were determined and were found within acceptable range. The method was found to be 
specific for the determination of particular analyte. Specificity was determined by injecting 
the analytical placebo(containing all excipient of tablet except amoxicillin and clavulanic 
acid). The interference by these excipients were determined by evaluating mixture of all 
excipient(placebo),standard solutions and commercial pharmaceutical preparations con-
tained amoxicillin and clavulanic acid within the same chromatographic condition.
The linearity of HPLC method was determined for amoxicillin and clavulanic acid. Ten dilutions 
of amoxicillin and eight dilutions clavulanic acid of different concentrations were prepared in 
mobile phase then sample size of 20 μl of each concentration was injected into HPLC. The detec-
tor response was measured at 235 nm and the calibration plots(concentration versus peak area) 
were obtained using the linear regression method. The linearity data showed linearity over a 
concentration range of 0.03–31.25 μg/ml for amoxicillin and 0.24–15.6 μg/ml for clavulanic acid. 
Repeatable and intermediate precision of method was determined. During the same day with the 
same experimental condition repeatability of four determination (n = 4) at the same concentra-
tion was calculated. The results of assay were compared and evaluated on three different days by 
different analyst for intermediate precision. The precision values for amoxicillin and clavulanic 
acid were found to be 0.91 and 0.35% for intraday and 0.89 and 0.34% for inter-day respectively.
The recovery studies were carried out for the assurance of reliability and accuracy of the 
proposed method. A known quantity of the drug added with preanalyzed sample and then 
reanalyzed by the proposed method. The recovery studies for amoxicillin and clavulanic acid 
were performed at three different concentrations corresponded to 80, 100 and 120% of active 
ingredients. For each concentration mean %recovery were from 99.7 to 101.4 for amoxicillin 
and 100 to 101.4% for clavulanic acid.
Small variation in the method parameters was created to measure its reliability during routine 
usage and the robustness. Not any significant effect on the method performance was observed 
by changing the flow rate of mobile phase, column temperature and ratio of organic content 
in mobile phase indicated that the test method was robust for all variable conditions (Table 1).
2.2. Pharmacokinetic evaluation of co-amoxiclav tablet
In Pakistan Co-amoxiclav tablet of 375 mg marketed by a multinational company Code #1 
Pakistan and a local company Code #2 (Table 2). Physico-chemical and potency determination 
Medium Parameters Amoxicillin Clavulanic acid
In mobile phase/plasma Limit of Quantification {LOQ(μg/ml)} 0.030/0.0075 0.243/0.12
Limit of Detection {LOD(μg/ml)} 0.015/0.0037 0.12/0.06
Table 1. Validation parameters of amoxicillin and clavulanic acid in mobile phase.
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Name of product Strength (mg) Date of mfg. Date of exp. Retail price (Rs) Industrial supplier
(AMCL1) 250/125 02–12 08–13 75.00 Code#1
(AMCL2) 250/125 04–12 04–14 82.00 Code#2
Note: This was a 2 year study and during this period we have taken products from different lots available in the market.
Table 2. Details of different amoxicillin/clavulanic acid products available in Pakistan.
from both sources of different batch were analyzed. This analysis was carried out just to com-
pare the two different brands available in Pakistan as an added parameter. The main objective 
of study is to conduct pharmacokinetic study of Co-amoxiclav tablet from a multinational 
company in local population and to find out difference in the pharmacokinetic parameters 
with the previous reported data due to racial inconsistency. It was preferred to compare only 
multinational brand because this has been most commonly prescribed by the prescriber to treat 
infections and the local brand did not proved to be as efficacious as that of multinational brand.
The study was two treatments, two sequences, single dose and cross over design in 12 nor-
mal healthy volunteers. An equal number of volunteers were assigned to each sequence. The 
study covers to determine the pharmacokinetic parameters i.e. Cmax, Tmax, AUC, rate con-
stant, Vd, total clearance and T½ of Co-amoxiclav in local population. The subjects engaged in 
the study were member of community at large and full-fill all of criteria to be included in the 
study. This criterion includes healthy males with normal vital signs, blood hematology and 
chemistry, non-smoker, able to consent and swallow. The study design was endorsed by the 
National Bioethics Committee, Ministry of Health, Government of Pakistan, Islamabad after 
critical ethical review and a written informed duly signed by volunteers has been taken. Four 
volunteers withdraw during study.
2.3. Bioanalytical validation
Plasma amoxicillin and clavulanic acid concentrations were determined using validated meth-
ods such as LC/MS/MS analysis (GTF) [8] (Table 3). The method was also validated according 
to International Council for Harmonization (ICH) guidelines (Figures 2 and 3).
The fundamental parameters of validation were Specificity, linearity, accuracy, precision, sensitiv-
ity, reproducibility, stability and robustness. All these parameters were determined and validated.
Product name % labeled strength Product name % labeled strength
AMCL1 106.1 CODE #1 113.38
AMCL2 119.8 CODE #2 109.9
Mean 112.9 111.64
S.D 9.6 2.46
>> Amoxicillin and clavulanate potassium tablets contain equivalent of not less than 90.0% and not more than 120.0% of 
the labeled amount of amoxicillin and clavulanic acid (USP 28).
Table 3. HPLC assay of different brands of amoxicillin/clavulanic acid tablet (250/125 mg) available in Pakistan.
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Mobile Phase containing methanol (10 volume) and 0.02 M disodium hydrogen phosphate buf-
fer (90 volume). The pH was adjusted to 3.0 by phosphoric acid. The mobile phase was filtered 
and degassed. An HPLC isocratic pump with UV–VIS detector was attached with RP 18e column 
(Hibar, 250 × 4.6 cm).
In a glass stoppered 15 ml centrifuge tube 0.75 ml of acetonitrile was added to 0.5 ml of plasma. 
After mixing(30s) the mixture centrifuged for 10 min at 5000 × g. Then 2.5 ml of dichlorometh-
ane was added to 300 μl of supernatant. After mixing (30 s) the mixture centrifuge for 10 min at 
5000 × g. Then 20 μl of supernatant was injected into liquid chromatograph at 235 nm detection 
wave length.
2.4. Pattern of variable absorption of clavulanic acid from different oral 
formulations of co-amoxiclav in healthy subjects
There has been no study to compare the difference of blood concentration time curve of dif-
ferent formulations of co-amoxiclav in local population of Pakistan. Therefore author tried 
to focus on the Pharmacokinetic pattern especially of clavulanic acid. It is due to fact that 
absorption of clavulanic acid, after oral administration, is highly variable and may vary over a 
five-fold range between patients [9]. Based on the plasma amoxicillin and clavulanic acid con-
centrations of individual subjects, were calculated by applying both compartmental and non-
compartmental method of analysis. As best fitted pharmacokinetic model one compartmental 
Figure 2. Linearity curve of clavulanic acid: conc vs. area showing linearity between standard solution and peak area.
Figure 3. Linearity curve of amoxicillin: conc vs. area showing linearity between standard solution and peak area.
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model with lag time, first order absorption and first order elimination was selected for both 
amoxicillin and clavulanate potassium.
The software Kinetica™ Ver 4.4.1. (Thermo Electron Corporation, USA) used to determine all 
parameters including both compartmental and non-compartmental analysis and interrelated 
for any variation in AUCt and demographic facts. The parameters determined were:
Cmax, Tmax (observed and calculated), Ka, Kel, T½ ka, T½α. AUC0−t, AUC0−α, ƛz, Vz, Vss, 
AUC last. AUC extrapolated, AUC total, %AUC extrapolated, AUMC and MRT.
where Cmax is maximum plasma concentration of drug(mg/L), Tmax is time required to 
achieve Cmax(h), Ka is absorption rate constant, AUC0−t, AUC0−α, AUC last with the help of 
linear trapezoidal method to find area under plasma-concentration time curve up to last mea-
surable concentration (mg.h./L),Kel is elimination half-life (h), ƛz is terminal rate constant, 
Vz is apparent volume of distribution during terminal phase (L/kg), Vss is apparent volume 
of distribution at steady state (L/kg), AUMC is area under the first moment of concentration-
time curve from time zero to infinity (amount.(time)2/volume) and MRT is mean residence 
time (h).
The mean ± plasma concentration time-curve of co-amoxiclav (250/125 mg) tablet of formula-
tion 1 is shown in Figure 4 in healthy volunteers (n = 8). The other formulation showed similar 
results. The half-life of all both formulation was 1.34 ± 0.06 h for amoxicillin and 1.20 ± 0.03 h 
for clavulanic acid.
The area under the concentration-time curve of clavulanic acid is the best measure of the 
absorption and beneficial effects in the recipient. Calculating the area under the curve using 
trough and peak blood levels versus using isolated readings for either of these levels alone is 
the most effective method of monitoring.
The mean AUC0−α values calculated through compartmental analysis were 26.81 ± 0.70 μg.h/
ml for amoxicillin while for clavulanate potassium 7.90 ± 0.13 μg.h/ml. The values of mean 
AUClast and AUCtot from non-compartmental analysis were 23.33 ± 0.70 and 27.96 ± 0.76 μg.h/
ml for amoxicillin. The clavulanate potassium showed the values of AUC last and AUC tot 
were 7.05 ± 0.11 and 7.70 ± 0.16 μg.h/ml.
Figure 4. Comparison of mean (±S.D) plasma-concentration time profile of amoxicillin and clavulanic acid after oral dose 
of 250/125 mg co-amoxiclav tablet (n-8: Formulation 1).
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The maximum concentration Cmax of amoxicillin was achieved in 1.85 ± 0.01 h for amoxicillin 
in compartmental. Similarly Cmax for clavulanate potassium was achieved in 1.56 ± 0.01 h in 
compartmental analysis (Tables 4 and 5).
The reported values of Vss after IV administration for amoxicillin is 0.28 ± 0.06 L/kg, and the 
Vss of clavulanic acid as 0.24 ± 0.06 L/kg, showing ratio for the volume of distribution between 
clavulanic acid and amoxicillin as 0.8571 [14] and therefore on the basis of this the ratio of 
amoxicillin to clavulanic acid AUCs should be 3.4. when co-amoxiclav is at dose of 250/125. The 
author observed in this study, the lowest AUCt amoxicillin/clavulanic acid ratio was 2.7 ± 0.50 
at the lower doses used. This would assume equal absorption of both amoxicillin and clavu-
lanic acid. But in the same dose amoxicillin/clavulanic acid AUCt ratios was higher that would 
suggest that with a similar amoxicillin absorption, clavulanic acid absorption must have been 
reduced. The reported absolute bioavailability of clavulanic acid, when co-administered with 
amoxicillin has been ranged from 31.4 to 98.8% [10]. Further it is reported that there is no major 
alteration in the mean AUCt of 125 mg clavulanate when it is administered along 500 mg of 
amoxicillin, but it creates marked impact on the coefficient of variation for the AUC which alter 
from 27.6% for clavulanic acid alone to 45.6% when given with amoxicillin [15]. Various other 
studies showed mean absorption up to 97% when clavulanic acid administered alone with 
minor inter-patient variability. It indicates interaction between absorption of amoxicillin and 
clavulanic acid [11, 12] . The author further found that there was no significant variation in the 
AUC observed for amoxicillin in this study either among subjects, on the basis of demographic 
data, or between formulations, once corrected for the dose. On the contrary, high variability 
was seen between subjects in the AUC of clavulanic acid (Figure 5). There were all healthy male 
subjects (with normal renal function), and it is difficult to explain the high variability seen in 
the clavulanic acid AUC on patient factors. However, it has been reported in other studies [13]. 
Also study observed broadened Tmax i.e. increase lag time indicating a rate limiting step in the 
absorption process. The authors being able to show that two different co-amoxiclav formula-
tions each gave a variation in the absorption, or in the AUCt value, of clavulanic acid for the 
same 125 mg dose.
In a study reported broadened Tmax with high dose of amoxicillin (875 mg) indicate a rate 
limiting step in the absorption and support previous other studies [16].
In this study the authors tried to show variation in the absorption or in AUCt value of cla-
vulanic acid at 125 mg dose with two formulations. Although we did not find any report of 
therapy failure among the patients due to this variation and its clinical efficacy has been main-
tained. It would suggest that it is more important to focus on the absolute or fixed amount of 
clavulanic acid rather than on its plasma concentration.
Formulation Dose (mg) T 
1/2
 (h) T
max
 (h) C
max
 (μg/L) AUC (μg.h/L)
AMCL1 125 1.20 ± 0.02 1.56 ± 0.01 2.60 ± 0.03 8.30 ± 0.06
AMCL2 125 1.21 ± 0.03 1.54 ± 0.02 1.98 ± 0.70 7.90 ± 0.13
Table 4. Pharmacokinetic parameters of clavulanic acid.
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3. Conclusions
In conclusion, variable absorption nature of clavulanic acid has been highlighted with altera-
tion in AUCt ratio of co-amoxiclav without any known cause. However, it is evident from 
clinical data that there is not any variability in the efficacy of co-amoxiclav and that the cur-
rent dosage ratio of 4:1 holds a traditional value.
The study requires further evaluation to find out the reason for this variation.
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Formulation Dose (mg) T
1/2
 (h) T
max
 (h) C
max
 (μg/L) AUC (μg.h/L)
AMCL1 250 1.34 ± 0.06 1.85 ± 0.01 2.98 ± 0.27 26.81 ± 0.70
AMCL2 250 1.32 ± 0.05 1.83 ± 0.02 3.3 ± 1.12 26.98 ± 0.83
Table 5. Pharmacokinetic parameters of amoxicillin.
Figure 5. Individual AUCts of amoxicillin plotted versus the AUCts of clavulanic acid. It can be seen that there is a 
variation in the AUCts of clavulanic acid, with little variation in those of amoxicillin (95% confidence interval).
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